Dimensional Fund Advisors LP Trims Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Dimensional Fund Advisors LP cut its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 552,432 shares of the medical instruments supplier's stock after selling 23,233 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.46% of LeMaitre Vascular worth $50,902,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in LMAT. Smartleaf Asset Management LLC boosted its holdings in shares of LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC grew its position in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV increased its stake in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares during the period. Huntington National Bank raised its holdings in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after buying an additional 455 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $150,000. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on LMAT shares. Lake Street Capital upped their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.14.

LeMaitre Vascular Stock Up 2.2 %

NASDAQ LMAT traded up $1.74 during mid-day trading on Monday, hitting $80.44. The stock had a trading volume of 355,694 shares, compared to its average volume of 163,672. The company has a 50 day simple moving average of $85.58 and a 200 day simple moving average of $93.37. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 43.96, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same period last year, the firm earned $0.44 EPS. The company's quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.